A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Inclusion Criteria: * Patients participated voluntarily and signed informed consent； * PTCL confirmed by histopathology； * There must be at least one evaluable or measurable lesion that meets Lugano2014 criteria； * The ECOG score is 0 to 1； * ANC≥1.5×10\*9/L，PLT≥75 × 10\*9/L；HB≥80 g/L；TBIL≤1.5ULN；ALT or AST≤2.5 ULN； Scr≤1.5ULN； * Use contraception during treatment and for one year after the end of treatment. Exclusion Criteria: * Patients with central nervous system (CNS) involvement and/or hemophagocytic syndrome； * The estimated survival time is less than 6 months； * History of allergy to anthracyclines or liposomes; Previous recipients of mitoxantrone or mitoxantrone liposome;Previous treatment with doxorubicin or other anthracyclines had a cumulative dose of doxorubicin \> 360 mg/m2（For other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin, and the maximum cumulative dose of liposomal doxorubicin is 2460mg/m2）； * The use of Chidamide is contraindicated; * Impaired heart function or significant heart disease; * Hepatitis B, hepatitis C active stage infection; * Had undergone major surgery within 4 to 6 weeks prior or expected to undergo major surgery during the study; * severe infection; * Poorly controlled high blood pressure or diabetes; * A history of active visceral bleeding within the previous 3 months * A history of malignancy within five years; * History of mental illness; * A history of substance abuse or dependence; * pregnant or lactating woman; * The investigators did not consider it appropriate to participate in this study.